Skip to content

Advanced Platelet Rich Fibrin in Periodontal Angular Defects

Evaluation of Advanced Platelet-rich Fibrin in Management of Periodontal Intrabony Defects

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03433066
Enrollment
22
Registered
2018-02-14
Start date
2018-03-01
Completion date
2019-06-30
Last updated
2019-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrabony Periodontal Defect

Keywords

advanced platelet-rich fibrin

Brief summary

The aim of this study is to clinically and radiographically evaluate the efficacy of advanced platelet-rich fibrin (A-PRF) when used with biphasic alloplast in the management of intrabony defects in patients with moderate to severe chronic periodontitis.

Detailed description

Biphasic alloplasts have been successfully used in management of intrabony defects. Advanced platelet-rich fibrin is believed to contain higher amount of growth factors and white blood cells than the well known PRF. Although there are some studies on the use of PRF in the treatment of intrabony defects, to date none of them evaluate the effect of the A-PRF. Therefore, a randomized controlled clinical trial was conducted to compare the healing of intrabony defects treated with A-PRF/biphasic alloplast combination and to those obtained with biphasic alloplast mixed with saline. Using a parallel arm design, 22 intrabony defects were randomly treated with either biphasic alloplast mixed with saline (control group) or with A-PRF/ biphasic alloplast combination (test group). The following clinical parameters were recorded at baseline, three and six months postoperatively : plaque index (PI), modified gingival index (MGI), probing depth (PD), clinical attachment level (CAL), while these radiographic measurements were recorded at baseline and six months postoperatively: bone fill and bone density.

Interventions

PROCEDUREAdvanced platelet-rich fibrin mixed with biphasic alloplast

mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.

PROCEDUREBiphasic alloplast mixed with saline

mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

This clinical study will be conducted on twenty-two (22) interproximal intrabony defects in patients with moderate to severe chronic periodontitis.These patients will be divided randomly into two groups: * Group I: (test) will include eleven interproximal intrabony defects that will be treated with (Advanced platelet rich fibrin & biphasic alloplast) * Group II: (control) will include eleven interproximal intrabony defects that will be treated with (biphasic alloplast mixed with saline.)

Eligibility

Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* They should be diagnosed as having moderate -severe chronic periodontitis according to the American Academy of Periodontology classification on gingival and periodontal diseases (1999) * Clinical attachment loss (CAL) ,radiographic evidence of the presence of at least one intrabony defect. * Patient's age between 25 to 55 years. * Both sexes. * No periodontal surgeries in the area of interest during the previous 6 months. * The presence of intrabony defects (IBD) ≥3 mm deep (distance between alveolar crest and deepest point in the defect estimated from radiographs and confirmed upon surgical exposure). * An interproximal probing depth (PD) ≥5 mm and clinical attachment loss (CAL) ≥3mm after phase I therapy in maxillary/ mandibular teeth. * The presence of an adequate zone of keratinized gingiva at the facial aspect of the selected tooth.

Exclusion criteria

* Patients who could not maintain O'leary plaque index (54) ≤10% after phase I therapy. * Aggressive periodontitis patients. * Patients with systemic conditions known to affect the periodontal status, or, under medications known to affect the outcomes of periodontal therapy. * Pregnancy/lactation. * Smoking and tobacco use in any form. * Non vital teeth and teeth with grade III mobility.

Design outcomes

Primary

MeasureTime frameDescription
Clinical attachment level changeBaseline , 3 and 6 months posoperativelyThe distance from cemento-enamel junction to the depth of the sulcus recorded by a periodontal probe at baseline , 3 and 6 months postoperatively

Secondary

MeasureTime frameDescription
Probing depth change:Baseline , 3 and 6 months postoperativelyThe distance from the gingival margin to the depth of the sulcus recorded by a periodontal probe at baseline and 6 months postoperatively
Radiographic bone densityBaseline and 6 months postoperativelyMeasuring the bone density before and after the procedure using CBCT
Radiographic bone fillBaseline and 6 months postoperativelyThe actual bone formation in the intrabony defect measured on a CBCT in comparison to the baseline CBCT

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026